{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:35:36Z","timestamp":1791063336160,"version":"4.1.0"},"reference-count":22,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,3,15]]},"abstract":"<jats:p>PURPOSE: Acute doxorubicin-induced cardiotoxicity can be prevented in adults by continuous infusion of the drug, but mechanisms of cardiotoxicity are different in children. We compared cardiac outcomes in children receiving bolus or continuous infusion of doxorubicin.<\/jats:p>\n                  <jats:p>\n                    PATIENTS AND METHODS: In a randomized study, children with high-risk acute lymphoblastic leukemia received doxorubicin 360 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    in 30-mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    doses every 3 weeks either by bolus (within 1 hour, n = 57) or by continuous infusion (over 48 hours, n = 64). Echocardiograms obtained before doxorubicin and at longest follow-up times were centrally remeasured, and z scores of cardiac measurements were calculated based on a healthy population.\n                  <\/jats:p>\n                  <jats:p>RESULTS: The groups were similar in age, sex distribution, doxorubicin dose, and duration of follow-up. Before treatment, measures of left ventricular (LV) structure and function did not reveal dilated cardiomyopathy and were not statistically different between bolus and continuous-infusion groups. The follow-up echocardiograms demonstrated no significant difference between the two groups for any cardiac characteristic, but both groups showed significant abnormalities of LV structure and function compared with normal and with baseline. For example, the mean LV fractional shortening fell by approximately two SD in both groups between the two echocardiograms. LV contractility was depressed in both groups (for bolus patients, median z score = \u22120.70 SD, P = .006; for continuous-infusion patients, median z score = \u22120.765, P = .005). Dilated cardiomyopathy and inadequate LV hypertrophy were noted in both groups. Clinical cardiac manifestations and event-free survival did not differ.<\/jats:p>\n                  <jats:p>CONCLUSION: Continuous doxorubicin infusion over 48 hours for childhood leukemia did not offer a cardioprotective advantage over bolus infusion. Both regimens were associated with progressive subclinical cardiotoxicity. Other cardioprotective strategies should be explored.<\/jats:p>","DOI":"10.1200\/jco.2002.20.6.1677","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T03:46:10Z","timestamp":1487907970000},"page":"1677-1682","source":"Crossref","is-referenced-by-count":121,"title":["Doxorubicin Administration by Continuous Infusion Is Not Cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol"],"prefix":"10.1200","volume":"20","author":[{"given":"Steven E.","family":"Lipshultz","sequence":"first","affiliation":[{"name":"From the Divisions of Pediatric Cardiology and Pediatric Hematology\/Oncology, Strong Children\u2019s Hospital and University of Rochester Medical Center, James P. Wilmot Cancer Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY; Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Division of Hematology\/Oncology and Department of Cardiology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Giantris","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Cardiology and Pediatric Hematology\/Oncology, Strong Children\u2019s Hospital and University of Rochester Medical Center, James P. Wilmot Cancer Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY; Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Division of Hematology\/Oncology and Department of Cardiology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart R.","family":"Lipsitz","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Cardiology and Pediatric Hematology\/Oncology, Strong Children\u2019s Hospital and University of Rochester Medical Center, James P. Wilmot Cancer Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY; Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Division of Hematology\/Oncology and Department of Cardiology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia Kimball","family":"Dalton","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Cardiology and Pediatric Hematology\/Oncology, Strong Children\u2019s Hospital and University of Rochester Medical Center, James P. Wilmot Cancer Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY; Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Division of Hematology\/Oncology and Department of Cardiology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara L.","family":"Asselin","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Cardiology and Pediatric Hematology\/Oncology, Strong Children\u2019s Hospital and University of Rochester Medical Center, James P. Wilmot Cancer Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY; Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Division of Hematology\/Oncology and Department of Cardiology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Barr","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Cardiology and Pediatric Hematology\/Oncology, Strong Children\u2019s Hospital and University of Rochester Medical Center, James P. Wilmot Cancer Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY; Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Division of Hematology\/Oncology and Department of Cardiology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Clavell","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Cardiology and Pediatric Hematology\/Oncology, Strong Children\u2019s Hospital and University of Rochester Medical Center, James P. Wilmot Cancer Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY; Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Division of Hematology\/Oncology and Department of Cardiology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Cardiology and Pediatric Hematology\/Oncology, Strong Children\u2019s Hospital and University of Rochester Medical Center, James P. Wilmot Cancer Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY; Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Division of Hematology\/Oncology and Department of Cardiology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Moghrabi","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Cardiology and Pediatric Hematology\/Oncology, Strong Children\u2019s Hospital and University of Rochester Medical Center, James P. Wilmot Cancer Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY; Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Division of Hematology\/Oncology and Department of Cardiology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"Samson","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Cardiology and Pediatric Hematology\/Oncology, Strong Children\u2019s Hospital and University of Rochester Medical Center, James P. Wilmot Cancer Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY; Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Division of Hematology\/Oncology and Department of Cardiology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall A.","family":"Schorin","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Cardiology and Pediatric Hematology\/Oncology, Strong Children\u2019s Hospital and University of Rochester Medical Center, James P. Wilmot Cancer Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY; Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Division of Hematology\/Oncology and Department of Cardiology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Gelber","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Cardiology and Pediatric Hematology\/Oncology, Strong Children\u2019s Hospital and University of Rochester Medical Center, James P. Wilmot Cancer Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY; Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Division of Hematology\/Oncology and Department of Cardiology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Sallan","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Cardiology and Pediatric Hematology\/Oncology, Strong Children\u2019s Hospital and University of Rochester Medical Center, James P. Wilmot Cancer Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY; Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Division of Hematology\/Oncology and Department of Cardiology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Colan","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Cardiology and Pediatric Hematology\/Oncology, Strong Children\u2019s Hospital and University of Rochester Medical Center, James P. Wilmot Cancer Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY; Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Division of Hematology\/Oncology and Department of Cardiology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School,..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-105146","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-96-2-133"},{"key":"R2-105146","unstructured":"Weiss  AJ,   Metter  GE,   Fletcher  WS,  et al:   Studies on Adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity.  Cancer Treat Rep 60:  813,1976-822,"},{"key":"R3-105146","unstructured":"Chlebowski  RT,   Paroly  WS,   Pugh  RP,  et al:   Adriamycin given as a weekly schedule without a loading course:  Clinically effective with reduced incidence of cardiotoxicity.   Cancer Treat Rep 64:  47,1980-51,"},{"key":"R4-105146","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890101)63:1<37::AID-CNCR2820630106>3.0.CO;2-Z"},{"key":"R5-105146","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D"},{"key":"R6-105146","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199103213241205"},{"key":"R7-105146","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506293322602"},{"key":"R8-105146","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"key":"R9-105146","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.545"},{"key":"R10-105146","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199210293271802"},{"key":"R11-105146","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199812)31:6<512::AID-MPO8>3.0.CO;2-4"},{"key":"R12-105146","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.13.926"},{"key":"R13-105146","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-99-6-745"},{"key":"R14-105146","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.3.207"},{"key":"R15-105146","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820501)49:9<1762::AID-CNCR2820490905>3.0.CO;2-Q"},{"key":"R16-105146","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910915)68:6<1221::AID-CNCR2820680607>3.0.CO;2-R"},{"key":"R17-105146","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931115)72:10<3120::AID-CNCR2820721038>3.0.CO;2-Q"},{"key":"R18-105146","doi-asserted-by":"crossref","unstructured":"Bielack  SS,   Ertmann  R,   Winkler  K,  et al:   Doxorubicin:  Effect of different schedules on toxicity and anti-tumor efficacy.   Eur J Cancer Clin Oncol 25:  8733,1989-8882,","DOI":"10.1016\/0277-5379(89)90135-1"},{"key":"R19-105146","unstructured":"Bielack  SS,   Fuchs  N,   Bieling  P,  et al:   Effect of doxorubicin (DOX) schedule on tumor response and survival in osteosarcoma (OS):  Results of sequential trials Coss 86 A-C. SIOP XXVI abstracts.   Med Pediatr Oncol 23:  176,1994  (abstr)"},{"key":"R20-105146","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.8.2641"},{"key":"R21-105146","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1980.165"},{"key":"R22-105146","unstructured":"Haskell  CM,   Sullivan  A:   Comparative survival in tissue culture of normal and neoplastic human cells exposed to Adriamycin.  Cancer Res 34:  2991,1974.2994,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.20.6.1677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T17:59:17Z","timestamp":1653501557000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.20.6.1677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3,15]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,3,15]]}},"alternative-id":["10.1200\/JCO.2002.20.6.1677"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.20.6.1677","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3,15]]}}}